Antiparasitics are a class of medications which are indicated for the treatment of parasitic diseases, such as those caused by helminths, amoeba, ectoparasites, parasitic fungi, and protozoa, among others. Antiparasitics target the parasitic agents of the infections by destroying them or inhibiting their growth; they are usually effective against a limited number of parasites within a particular class. Antiparasitics are one of the antimicrobial drugs which include antibiotics that target bacteria, and antifungals that target fungi. They may be administered orally, intravenously or topically.
Broad-spectrum antiparasitics, analogous to broad-spectrum antibiotics for bacteria, are antiparasitic drugs with efficacy in treating a wide range of parasitic infections caused by parasites from different classes.
- Melarsoprol (for treatment of sleeping sickness caused by Trypanosoma brucei)
- Eflornithine (for sleeping sickness)
- Metronidazole (for vaginitis caused by Trichomonas)
- Tinidazole (for intestinal infections caused by Giardia lamblia)
- Miltefosine (for the treatment of visceral and cutaneous leishmaniasis, currently undergoing investigation for Chagas disease)
- Mebendazole (for most nematode infections)
- Pyrantel pamoate (for most nematode infections)
- Thiabendazole (for roundworm infections)
- Diethylcarbamazine (for treatment of Lymphatic filariasis)
- Ivermectin (for prevention of river blindness)
- Niclosamide (for tapeworm infections)
- Praziquantel (for tapeworm infections)
- Albendazole (broad spectrum)
Drug development history
Between 1975 and 1999 only 13 of 1,300 new drugs were antiparasitics, which raised concerns that insufficient incentives existed to drive development of new treatments for diseases that disproportionately target low-income countries. This led to new public sector and public-private partnerships (PPPs), including investment by the Bill and Melinda Gates Foundation. Between 2000 and 2005, twenty new antiparasitic agents were developed or in development. In 2005, a new antimalarial cost approximately $300 million to develop with a 50% failure rate.
- Kappagoda, Shanthi; Singh, Upinder; Blackburn, Brian G. (2011). "Antiparasitic Therapy". Mayo Clin Proc. 6 (86): 561–583. doi:10.4065/mcp.2011.0203. PMC 3104918. PMID 21628620.
- Kusrini E, Hashim F, Azmi WN, Amin NM, Estuningtyas A (2016). "A novel antiamoebic agent against Acanthamoeba sp. - A causative agent for eye keratitis infection". Spectrochim Acta A Mol Biomol Spectrosc. 153: 714–21. doi:10.1016/j.saa.2015.09.021. PMID 26474244.
- Molina JM, Tourneur M, Sarfati C, et al. (June 2002). "Fumagillin treatment of intestinal microsporidiosis". N. Engl. J. Med. 346 (25): 1963–9. doi:10.1056/NEJMoa012924. PMID 12075057.
- "ANTIPARASITICS". Purdue University Cytology Laboratories. Purdue Research Foundation. Retrieved 2015-08-30.
- Di Santo N, Ehrisman J (2013). "Research perspective: potential role of nitazoxanide in ovarian cancer treatment. Old drug, new purpose?". Cancers (Basel). 5 (3): 1163–1176. doi:10.3390/cancers5031163. PMC 3795384. PMID 24202339.
Nitazoxanide [NTZ: 2-acetyloxy-N-(5-nitro-2-thiazolyl)benzamide] is a thiazolide antiparasitic agent with excellent activity against a wide variety of protozoa and helminths. ... Nitazoxanide (NTZ) is a main compound of a class of broad-spectrum anti-parasitic compounds named thiazolides. It is composed of a nitrothiazole-ring and a salicylic acid moiety which are linked together by an amide bond ... NTZ is generally well tolerated, and no significant adverse events have been noted in human trials . ... In vitro, NTZ and tizoxanide function against a wide range of organisms, including the protozoal species Blastocystis hominis, C. parvum, Entamoeba histolytica, G. lamblia and Trichomonas vaginalis 
- White CA (2004). "Nitazoxanide: a new broad spectrum antiparasitic agent". Expert Rev Anti Infect Ther. 2 (1): 43–9. doi:10.1586/14787220.127.116.11. PMID 15482170.
- Hemphill A, Mueller J, Esposito M (2006). "Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections". Expert Opin Pharmacother. 7 (7): 953–64. doi:10.1517/14656518.104.22.1683. PMID 16634717.
- Anderson, V. R.; Curran, M. P. (2007). "Nitazoxanide: A review of its use in the treatment of gastrointestinal infections". Drugs. 67 (13): 1947–1967. doi:10.2165/00003495-200767130-00015. PMID 17722965.
- Lanternier F, Boutboul D, Menotti J, et al. (February 2009). "Microsporidiosis in solid organ transplant recipients: two Enterocytozoon bieneusi cases and review". Transpl Infect Dis. 11 (1): 83–8. doi:10.1111/j.1399-3062.2008.00347.x. PMID 18803616.
- Pink, Richard; Hudson, Alan; Mouries, Marie-Annick; Bendig, Mary (September 2005). "Opportunities and Challenges in Antiparasitic Drug Discovery". Nature. 4: 727–740. doi:10.1038/nrd1824.